🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#APCCCD Advanced Prostate Cancer Consensus Conference Great times with the incredible Nick James also on @Prof-Nick-James.bsky.social and Piet Ost Wonderful debates, discussions of major trial gaps, learning the strengths weaknesses of each of our country’s health systems, and now I have a new podcast to listen to from Nick James also on @Prof-Nick-James.bsky.social.

A GREAT DAY 2 of #APCCCDiagnostics25 from Lugano silke gillessen 🇨🇭& aurelius omlin 🇨🇭 Give us their take of this inaugural edition of this meeting, unexpected surprises and leave us already looking forward to #APCCCDiagnostics27 Advanced Prostate Cancer Consensus Conference #ProstateCancer 🚨 OncoAlert

Hormone intensification at ADT initiation increases AR alterations at progression! 🧬 In STAMPEDE, AR gene alterations were significantly higher in patients receiving ADT + enzalutamide/abiraterone vs ADT alone! AttardLab Nick James also on @Prof-Nick-James.bsky.social JAMA Oncology Advanced Prostate Cancer Consensus Conference OncoAlert

Has indeed been a great meeting!

Latest from #STAMPEDE - intensified AR targeting drives increased prevalence of AR mutations at progression compared to monotherapy patient samples jamanetwork.com/journals/jamao… MRC Clinical Trials Unit at UCL The ICR AttardLab

Really powerful speech. We need to listen and act.

#Metformin study reveals weight management benefits for ADT therapy. silke gillessen and Neeraj Agarwal, MD, FASCO discuss the results of the #STAMPEDE trial's metformin arm. The phase 3 trial evaluates the addition of metformin to ADT in patients with #mHSPC. #FullVideo on UroToday >

Great to see the #STAMPEDE trial shortlisted for the National Institute for Health and Care Research Impact Prize 2025! 🏆 nihr.ac.uk/about-us/our-i… MRC Clinical Trials Unit at UCL Nick James also on @Prof-Nick-James.bsky.social Max Parmar AttardLab GU Cancer Research group The Christie NHS Manchester Cancer Research Centre

Two interviews on the latest STAMPEDE data on topical oestrogen in place of standard ADT The ICR MRC Clinical Trials Unit at UCL Published by VJ Oncology vjoncology.com/video/g0h6gyle…

Two interviews on the latest STAMPEDE data on topical oestrogen in place of standard ADT The ICR MRC Clinical Trials Unit at UCL Teh second interview: Published by VJ Oncology vjoncology.com/video/n0urhrxc…

Our RADIO trial safety data on chemoRt- immunotherapy with durvalumab for muscle invasive bladder cancer from GU ASCO. In a nutshell - its safe and deliverable Birmingham Cancer Research UK Clinical Trials Unit The ICR VJ Oncology vjoncology.com/video/fkxflf2o…

🎙 New Trials and Tribulations Podcast Episode with Prof Kevin Harrington, Head of Radiotherapy& Imaging The ICR and Consultant Oncologist The Royal Marsden NHS Foundation Trust! We delve into biological agents and clinical trials 🎧 open.spotify.com/episode/27WtMQ… Nick James also on @Prof-Nick-James.bsky.social Hoda Abdel-Aty 💙

Really interesting chat - how to design trials with injectables a challenging area. Also how to deal with issues like replication competent viruses in the COVID 19 conspiracy era touched upon!

Our third #NIHRImpactPrizes established investigator winner 🏆 is the STAMPEDE trial, for their multi arm platform trial to assess 10 different treatment approaches in men with advanced prostate cancer, leading to improvements in survival. Congratulations! The award was collected

Very proud to collect this award on behalf of the huge team that makes up the STAMPEDE trial MRC Clinical Trials Unit at UCL staff, at least 3000 site staff and of course 12000 patients and their families. #teamscience

Ashwin Sachdeva presented metabolic outcomes data from the #STAMPEDE metformin trial demonstrating that the addition of metformin to SOC mitigates adverse metabolic effects of ADT - this work was featured in the Best of #EAU25 ⭐️ session

Can’t even make their own MAGAhats

Interesting, but needs to be benchmarked against schedules that include RT. Good long term function and durable high bladder preservation rates

In the context of #MIBC, is #TURBT still needed? 🔍 Some experts propose replacing it with sample biopsy. Ready for the debate? Join the #UROwebinar and find out more from experts Paolo Gontero, Prof Param Mariappan FRCS(Urol), PhD, Nick James also on @Prof-Nick-James.bsky.social, and Alex Masson-Lecomte👇 webinars.uroweb.org/EAU/webinars/1…

Congrats Nick James also on @Prof-Nick-James.bsky.social & team👉@asco #ASCO25 👉a prognostic digital pathology based AI score (ArteraAI) identifies pts with clinically high-risk #prostatecancer (non metastatic) 👉likely to benefit most from adding abiraterone to SOC OncoAlert UroToday.com Prostate Cancer Foundation